Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

No abstract is available for this paper.

• Publication year

  2013

• Venue

  AIDS (London)

• Publication date

  2013-01-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/QAD.0b013e32835b2ef1PMID 23291539
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunosenescence and HIV.

  2012cited by this paper
• Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study *

  2011cited by this paper
• Premature age-related comorbidities among HIV-infected persons compared with the general population.

  2011cited by this paper
• Dyslipidemia related to antiretroviral therapy.

  2011influential reference
• Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

  2010influential reference
• Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.

  2008cited by this paper
• Class of antiretroviral drugs and the risk of myocardial infarction.

  2007cited by this paper
• Combination antiretroviral therapy and the risk of myocardial infarction.

  2003cited by this paper
• Combination antiretroviral therapy and the risk of myocardial infarction

  2003cited by this paper
• Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels.

  2002cited by this paper
• Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents

  1994cited by this paper

• Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV — CDC Recommendations, United States, 2025

  2025cites this paper
• Characterization and stratification of risk factors of stroke in people living with HIV: A theory-informed systematic review

  2025cites this paper
• HIV-Associated Cardiovascular Disease Pathogenesis: An Emerging Understanding Through Imaging and Immunology.

  2024cites this paper
• Prevention and treatment of cardiovascular disease in HIV: practical insights in an evolving field.

  2023cites this paper
• Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study

  2023cites this paper
• The Evolving Landscape of ASCVD Risk Among Patients With HIV.

  2022cites this paper
• Community-Engaged Intervention Mapping for Cardiovascular Disease Prevention in Black and Latinx Sexual Minority Men With HIV in New York City: Protocol for a Web-Based Mixed Methods Study

  2022cites this paper
• Real-world Safety Profile of Darunavir and its Boosted Agents: An Analysis of FDA Adverse Event Reporting System Database

  2021cites this paper
• Protease Inhibitors

  2021cites this paper
• Clinical and angiographical features of first episode of acute coronary syndrome in patients with human immunodeficiency virus infection

  2021cites this paper
• Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database

  2021cites this paper
• Cardiovascular risks associated with protease inhibitors for the treatment of HIV

  2021cites this paper
• Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

  2020cites this paper
• Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy.

  2020cites this paper
• Heart Failure and Human Immunodeficiency Virus

  2020cites this paper
• HIV/AIDS : Antiretroviral Drugs

  2020cites this paper
• Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

  2019cites this paper
• Cardiac Surgery in HIV Patients: State of the Art.

  2019cites this paper
• Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status

  2019cites this paper
• Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care.

  2019cites this paper
• Two-drug regimens with dolutegravir for maintaining viral suppression: looking at the right companion.

  2019cites this paper
• Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association.

  2019cites this paper
• Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis

  2019cites this paper
• Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

  2019cites this paper
• HIV infection and coronary heart disease: mechanisms and management

  2019cites this paper
• AHA SCIENTIFIC STATEMENT Characteristics , Prevention , and Management of Cardiovascular Disease in People Living With HIV A Scientific Statement From the American Heart Association Circulation

  2019cites this paper
• Stroke in HIV.

  2019cites this paper
• HIV-associated cardiovascular disease: importance of platelet activation and cardiac fibrosis in the setting of specific antiretroviral therapies

  2018cites this paper
• Understanding mechanisms to promote successful aging in persons living with HIV.

  2018cites this paper
• Subclinical cardiovascular disease in patients starting contemporary protease inhibitors

  2018cites this paper
• Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.

  2018cites this paper
• Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir

  2018cites this paper
• Plasma glycomics predict cardiovascular disease in patients with ART‐controlled HIV infections

  2018cites this paper
• Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression

  2018cites this paper
• Managing antiretroviral therapy in the elderly HIV patient

  2018cites this paper
• Electrocardiographic Abnormalities Among HIV Infected Adults Attending The Comprehensive Care Center At Kenyatta National Hospital

  2018cites this paper
• Prise en charge de l’infection par le virus de l’immunodéficience humaine

  2018cites this paper
• Atazanavir sulfate + cobicistat for the treatment of HIV infection

  2017cites this paper
• Seguimiento y actitud terapéutica de la infección por el virus de la inmunodeficiencia humana

  2017cites this paper
• Cardiovascular Disease and Cardiovascular Disease Risk in HIV-Positive Populations in the Asian Region

  2017cites this paper
• Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir

  2017cites this paper
• HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm

  2017cites this paper
• Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

  2017cites this paper
• Cardiovascular outcomes among HIV-infected veterans receiving atazanavir

  2017cites this paper
• Impact of CCR5, Integrase and Protease Inhibitors on Human Endothelial Cell Function, Stress, Inflammation and Senescence

  2017cites this paper
• Relationship Between HIV Infection, Antiretroviral Therapy, Inflammatory Markers, and Cerebrovascular Endothelial Function Among Adults in Urban China

  2017cites this paper
• Atteintes cardiovasculaires au cours de l’infection par le virus de l’immunodéficience humaine

  2017cites this paper
• Cardiovascular disease in women with HIV-1 infection.

  2017cites this paper
• Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults

  2016cites this paper
• LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation.

  2016cites this paper
• Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART.

  2016cites this paper
• Statins to improve cardiovascular outcomes in treated HIV infection

  2016cites this paper
• Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection

  2016cites this paper
• Inflammation, immune activation, and cardiovascular disease in HIV.

  2016cites this paper
• British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2015

  2016cites this paper
• Relationship between plasma bilirubin level and oxidative stress markers in HIV‐infected patients on atazanavir‐ vs. efavirenz‐based antiretroviral therapy

  2016cites this paper
• Lipid Abnormalities and Inflammation in HIV Inflection

  2016cites this paper
• Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in Older Adults.

  2016cites this paper
• HIV Infection and Myocardial Infarction.

  2016cites this paper
• Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review

  2016cites this paper
• Managing Cardiovascular Risk in People Living with HIV

  2016cites this paper
• An Open-Label, Randomized Study of the Impact on Insulin Sensitivity, Lipid Profile and Vascular Inflammation by Treatment with Lopinavir/Ritonavir or Raltegravir in HIV-Negative Male Volunteers

  2016cites this paper
• Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV

  2016cites this paper
• Suivi et prise en charge thérapeutique de l⿿infection par le virus de l⿿immunodéficience humaine

  2016cites this paper
• Contribution of antiretroviral therapy to cardiovascular disease risk in HIV-infected patients

  2016cites this paper
• Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial

  2016cites this paper
• Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy

  2016cites this paper
• Pathophysiology and Management of Cardiovascular Disease in HIV-Infected Patients

  2016cites this paper
• Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study

  2016cites this paper
• Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

  2015cites this paper
• A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era

  2015cites this paper
• Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?

  2015cites this paper
• Cardiovascular disease in HIV patients: from bench to bedside and backwards

  2015cites this paper
• Patterns of HIV, TB, and non-communicable disease multi-morbidity in an informal peri-urban setting in Cape Town, South Africa

  2015cites this paper
• Cardiovascular surgery outcomes of patients with human immunodeficiency virus infection: New data in the era of combination antiretroviral therapy.

  2015cites this paper
• Dyslipidemia in HIV-Infected Patients

  2015cites this paper
• Dyslipidemia in HIV

  2015cites this paper
• New strategies to optimize treatment for HIV-1 infection

  2015cites this paper
• Epidemiology and Management of Antiretroviral-Associated Cardiovascular Disease

  2015cites this paper
• Why the communicable/non-communicable disease dichotomy is problematic for public health control strategies: implications of multimorbidity for health systems in an era of health transition

  2015cites this paper
• Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

  2015cites this paper
• Epidemiology of coronary heart disease in HIV-infected versus uninfected individuals in developed countries.

  2015cites this paper
• Epidemiology of Coronary Heart Disease in HIV Patients

  2014cites this paper
• Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

  2014cites this paper
• Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study

  2014cites this paper
• Epidemiology of coronary heart disease in patients with human immunodeficiency virus.

  2014cites this paper
• Chapter 29 – Antiviral Drugs

  2014cites this paper
• Preventing Heart Failure in Inflammatory and Immune Disorders

  2014cites this paper
• Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia: Translating Clinical Trial Experience Into Clinical Practice

  2014cites this paper
• Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?

  2014cites this paper
• Risk of coronary heart disease in patients with HIV infection

  2014cites this paper
• Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results

  2014cites this paper
• Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.

  2014cites this paper
• Human Immunodeficiency Virus (HIV) and Stroke Events: A Systematic Review and Meta-Analysis

  2014cites this paper
• Infectious causes of stroke.

  2014cites this paper
• Metabolic Effects of Ritonavir-boosted Atazanavir and Darunavir in HIV negative Adults: A Randomised Comparison

  2014cites this paper
• Changes in Biomarkers in HIV-1-Infected Treatment-Naive Patients Treated with Tenofovir DF/Emtricitabine plus Atazanavir/Ritonavir or Lopinavir/Ritonavir for 96 Weeks: The CASTLE Biomarker Substudy

  2014cites this paper
• Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort

  2014cites this paper
• Heart failure in HIV infection: focus on the role of atherosclerosis

  2014cites this paper
• Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure.

  2014cites this paper